바이오시밀러 시장 규모 조사 : 약물 종류별, 적응증별, 지역별 예측(2022-2032년)

Global Biosimilar Market is valued at approximately USD 29.4 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 17.8% over the forecast period 2024-2032. Biosimilars, which are almost identical copies of original biologic products but manufactured by different companies, are increasingly being utilized to treat a wide range of chronic and acute diseases. These follow-on biologics have significantly impacted the healthcare landscape due to their potential to provide more affordable therapeutic options compared to original biologics. The resurgence in biosimilar approvals and launches, post the COVID-19 pandemic, has invigorated market expansion.

The launch of novel biosimilars is significantly impacting the global biosimilar market by providing more affordable alternatives to existing biologic therapies, which is expected to drive market growth. Biosimilars are biologic medical products highly similar to already approved reference biologics, offering comparable efficacy and safety at a lower cost. The increasing number of biosimilar approvals and launches is accelerating market expansion, as biosimilars are expected to save billions in healthcare costs. Moreover, the emerging markets and extended therapeutic uses present various lucrative opportunities over the forecast years. However, the complexities in manufacturing, increased competition and regulatory hurdles are challenging the market growth throughout the forecast period of 2024-2032.

The key regions considered for the Global Biosimilar Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Global Biosimilar Market in terms of revenue. The market growth in the region is being attributed to factors including advanced healthcare infrastructure, high prevalence of chronic diseases, and significant investment in biotechnology. The United States leads the market due to its large patient population, supportive regulatory environment, and substantial presence of key biosimilar manufacturers such as Amgen and Pfizer. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by increasing healthcare needs due to a rising prevalence of chronic diseases, expanding access to healthcare, and supportive government policies. Countries like China and India are investing heavily in biosimilar production and are experiencing a surge in demand due to their large patient populations and growing healthcare infrastructure.

Major market players included in this report are:

• Orion Pharma AB
• Samsung Bioepis
• Coherus BioSciences, Inc.
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Bristol-Myers Squibb Company
• Merck KGaA
• Teva Pharmaceutical Industries Ltd.
• Biocon
• Bayer AG
• AbbVie Inc.
• Allergan
• Dr. Reddy's Laboratories Ltd.
• Boehringer Ingelheim International GmbH
• Biogen

The detailed segments and sub-segment of the market are explained below:

By Drug Class:

• Monoclonal Antibodies
• Insulin
• Granulocyte Colony-Stimulating Factor
• Erythropoietin
• Recombinant Human Growth Hormone
• Etanercept
• Follitropin
• Teriparatide
• Interferons
• Anticoagulants
• Other Drug Class

By Indication:

• Oncology
• Inflammatory & Autoimmune Disorders
• Chronic Diseases
• Blood Disorders
• Growth Hormone Deficiency
• Infectious Diseases
• Other Indications

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Biosimilar Market Executive Summary

• 1.1. Global Biosimilar Market Size & Forecast (2022- 2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Drug Class
  • 1.3.2. By Indication
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Biosimilar Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Biosimilar Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Launch of Novel Biosimilars
  • 3.1.2. Strong R&D Pipeline
• 3.2. Market Challenges
  • 3.2.1. Complexities in Manufacturing
  • 3.2.2. Increased Competition and Regulatory Hurdles
• 3.3. Market Opportunities
  • 3.3.1. Emerging Markets
  • 3.3.2. Extended Therapeutic Uses

Chapter 4. Global Biosimilar Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Biosimilar Market Size & Forecasts by Drug Class 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Biosimilar Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Monoclonal Antibodies
  • 5.2.2. Insulin
  • 5.2.3. Granulocyte Colony-Stimulating Factor
  • 5.2.4. Erythropoietin
  • 5.2.5. Recombinant Human Growth Hormone
  • 5.2.6. Etanercept
  • 5.2.7. Follitropin
  • 5.2.8. Teriparatide
  • 5.2.9. Interferons
  • 5.2.10. Anticoagulants
  • 5.2.11. Other Drug Class

Chapter 6. Global Biosimilar Market Size & Forecasts by Indication 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Biosimilar Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Oncology
  • 6.2.2. Inflammatory & Autoimmune Disorders
  • 6.2.3. Chronic Diseases
  • 6.2.4. Blood Disorders
  • 6.2.5. Growth Hormone Deficiency
  • 6.2.6. Infectious Diseases
  • 6.2.7. Other Indications

Chapter 7. Global Biosimilar Market Size & Forecasts by Region 2022-2032

• 7.1. North America Biosimilar Market
  • 7.1.1. U.S. Biosimilar Market
    • 7.1.1.1. Drug Class breakdown size & forecasts, 2022-2032
    • 7.1.1.2. Indication breakdown size & forecasts, 2022-2032
  • 7.1.2. Canada Biosimilar Market
• 7.2. Europe Biosimilar Market
  • 7.2.1. U.K. Biosimilar Market
  • 7.2.2. Germany Biosimilar Market
  • 7.2.3. France Biosimilar Market
  • 7.2.4. Spain Biosimilar Market
  • 7.2.5. Italy Biosimilar Market
  • 7.2.6. Rest of Europe Biosimilar Market
• 7.3. Asia-Pacific Biosimilar Market
  • 7.3.1. China Biosimilar Market
  • 7.3.2. India Biosimilar Market
  • 7.3.3. Japan Biosimilar Market
  • 7.3.4. Australia Biosimilar Market
  • 7.3.5. South Korea Biosimilar Market
  • 7.3.6. Rest of Asia Pacific Biosimilar Market
• 7.4. Latin America Biosimilar Market
  • 7.4.1. Brazil Biosimilar Market
  • 7.4.2. Mexico Biosimilar Market
  • 7.4.3. Rest of Latin America Biosimilar Market
• 7.5. Middle East & Africa Biosimilar Market
  • 7.5.1. Saudi Arabia Biosimilar Market
  • 7.5.2. South Africa Biosimilar Market
  • 7.5.3. Rest of Middle East & Africa Biosimilar Market

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
• 8.2. Top Market Strategies
• 8.3. Company Profiles
  • 8.3.1. Orion Pharma AB
    • 8.3.1.1. Key Information
    • 8.3.1.2. Overview
    • 8.3.1.3. Financial (Subject to Data Availability)
    • 8.3.1.4. Product Summary
    • 8.3.1.5. Market Strategies
  • 8.3.2. Samsung Bioepis
  • 8.3.3. Coherus BioSciences, Inc.
  • 8.3.4. Eli Lilly and Company
  • 8.3.5. Takeda Pharmaceutical Company Limited
  • 8.3.6. Bristol-Myers Squibb Company
  • 8.3.7. Merck KGaA
  • 8.3.8. Teva Pharmaceutical Industries Ltd.
  • 8.3.9. Biocon
  • 8.3.10. Bayer AG
  • 8.3.11. AbbVie Inc.
  • 8.3.12. Allergan
  • 8.3.13. Dr. Reddy's Laboratories Ltd.
  • 8.3.14. Boehringer Ingelheim International GmbH
  • 8.3.15. Biogen

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes